vival [hazard ratio 3.3, p > 0.05, 95% confidence interval 0.7-16.2]. Twenty-one tumour blocks were tested for EpCAM and stathmin immunohistochemistry (IHC). Stathmin tumour immunostaining scores (TIS) on IHC were higher in CTC-positive patients. Conclusion: CTC enumeration and molecular profiling with stathmin on the CellSearch platform is feasible in aEC. Stathmin TIS on IHC, a known prognostic marker in EC, was associated with CTC positivity.
Introduction
Despite being the most common gynaecological malignancy in the developed world and 4th most common women's cancer in the UK [1] , endometrial cancer (EC) treatment is limited to standard chemotherapy with no approved molecularly targeted therapies. Although 75% of patients present with surgically resectable early-stage disease, those with regional and distant metastases have poor outcomes and limited treatment options. The currently used prognostic and predictive parameters that guide patient management in EC are based on historical clinicopathologic factors, without correlation with molecular aberrations.
Circulating tumour cells (CTCs) are cancer cells known to circulate in the peripheral blood of cancer patients and are not detected in healthy individuals [2] . As CTCs can be analysed from a simple blood draw, their use for prognostic and predictive purposes and to assess drug response and resistance is appealing. Novel technologies also allow molecular characterisation on CTCs that could assist with treatment selection and identify changes in the molecular profile of an individual's tumour over time [3] [4] [5] [6] .
Numerous techniques for the isolation and enumeration of CTCs have been reported, but only the CellSearch (Janssen) method is analytically validated and FDA approved for use for prostate, breast and colorectal cancers [7] [8] [9] . CellSearch relies on detection of epithelial cell adhesion molecule (EpCAM), which has a reported high expression in EC of 65-80% across all grades and stages [10] . As such, we investigated whether CTCs were present and could be enumerated in patients with advanced EC.
Within the CellSearch system, there is a fourth channel in which a fluorescein-conjugated antibody of interest, stathmin in this study, can be analysed along with routine CTC morphological and staining features. Stathmin is a cytosolic phosphoprotein and regulator of the microtubule cytoskeleton and cell cycle [11] and is also a highly relevant biomarker in EC [12] , with overexpression demonstrated in between 27 and 57% [12] . It has prognostic significance in several malignancies, including EC [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , and there is evidence for its prognostic and predictive value for metastases [12, 21] and response to taxane chemotherapy [20, [23] [24] [25] . There is also evidence for stathmin as a surrogate marker of phosphoinositide 3-kinase (PI3K) pathway activation [19] , one of the most commonly aberrant pathways in EC, and is associated with phosphatase and tensin homologue (PTEN) loss and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) amplification [19, 26] . Thus, longitudinal assessment of stathmin expression may further establish its role as a predictive marker of PI3K activation and in monitoring response to PI3K inhibition.
CTC enumeration and molecular profiling (MP), if feasible, may provide one of the first predictive biomarkers to monitor patients' treatment in EC and allow for longitudinal assessment of molecular changes to assist with targeted therapy development.
Methods

Study Design
Patients with histologically confirmed stage III and IV endometrioid (EEC) and non-endometrioid EC (NEEC) were eligible. Patients were >18 years of age and assessed at any time point of their treatment, including before surgery, before and after radiotherapy or before, during and after chemotherapy. Exclusion criteria included prior history of another cancer within the last 5 years, except non-melanoma skin cancer. CTC enumeration was performed every 3-6 months or if there was a change in clinical status, with up to 4 samples taken per patient.
After local Research Ethics Committee and institutional approval, patients from University College London Hospitals (UCLH) and Sarah Cannon Research Institute UK (SCRI UK) participated between October 2012 and February 2014. All patients provided written informed consent.
For patients whose archival tumour tissue was held at UCLH Histopathology Department, EpCAM and stathmin immunohistochemistry (IHC) was performed. Clinical data including demographic, clinicopathologic information, details of treatment, disease recurrence and survival were retrieved from the UCLH and SCRI UK patient information systems.
Isolation and Enumeration of CTCs
At each time point, a peripheral blood sample of up to 15 ml (2 × 7.5 ml) for CTC isolation and enumeration was collected in two CellSave Preservative tubes (Cat. No. 7900005) and maintained at room temperature. Each specimen was processed within 96 h of being received at the UCL Cancer Institute by trained laboratory staff who were blinded as to the clinical status of each patient.
Using the CellSearch CTC kit on the Celltracks Autoprep system, cells expressing EpCAM were immunomagnetically identified. Cells were then fluorescently labelled with 4 ′ 6-diamidino-2-phenylindole (DAPI), cytokeratin 8, 18, 19-phycoerythrin (CK-PE) and CD45-allophycocyan (CD45-APC) to identify nuclear, cytokeratin and leucocyte staining, respectively. The CellTracks Analyzer II (Cat. No. 9555 RUO), a four-colour semi-automated fluorescence microscope, was then used for scanning and reconstruction of cellular images, which were reviewed by trained laboratory staff. CTCs were defined as positive for CK-PE and DAPI, negative for CD45-APC and having the correct morphology to be characterised as a tumour cell. FITC-conjugated stathmin antibody (at 50 μg/ml, Biorbyt Cat. No. orb 14103) was used in the fourth channel.
FFPE Tissue Processing and IHC Assessment
For patients who had a biopsy or surgery performed at UCLH, EpCAM (1/4 dilution; mouse anti-human, RTU-ESA; Novocastra, Newcastle, UK) and stathmin (1/30 dilution; 3352 Cell Signalling, UK) IHC were performed on the available FFPE tumour blocks.
Each archival tumour block was sectioned at 3-μm thickness onto charged slides, drained and baked at 60 ° C for 60 min. Unstained slides were labelled and placed for IHC staining of EpCAM and stathmin primary antibodies on the Leica Bond III autostainer platform, using the Bond Polymer Refine Detection Kit (Cat. No. DS9800). The methodology and specific protocols for each primary antibody are outlined in the online supplementary material (see www.karger.com/doi/10.1159/000445999 for all online suppl. material).
The EpCAM and stathmin IHC analyses were interpreted with a consultant gynae-oncology histopathologist, who was blinded as to the CTC status of each patient. A tumour immunostaining score (TIS) was generated, as previously published for both EpCAM and stathmin [12, 27, 28] . The TIS is a product of a proportion score and an intensity score. For EpCAM expression, the proportion score describes the estimated fraction of positively stained tumour cells (0: none; 1: <10%; 2: 10-50%; 3: 51-80%; 4: >80%). The intensity score represents the estimated staining intensity as compared with a normal FFPE control (0: no staining; 1: weak; 2: moderate; 3: strong). The TIS ranges from 0 to 12 and is classified into 4 subgroups as follows: no expression (TIS 0), weak (TIS 1-4), moderate (TIS 6 and 8) and intense expression (TIS 9 and 12) [28] . The stathmin TIS is also the product of staining intensity, scored as per the EpCAM scoring system, and the area of tumour with positive staining (0: no staining, 1: <10%, 2: 10-50%, 3: >50% of tumour cells). The range is 0-9 [12] with moderate/intense expression as an index ≥ 4/9 and absent/minimal expression as an index <4, with a high protein level defined as the upper quartile [27, 29] , as has been previously reported [12, 27] .
Statistical Analysis
Statistical analysis was performed using Stata, version 12.1. Kaplan-Meier curves were generated for time to recurrence and overall survival. p values <0.05 were considered statistically significant.
Results
A total of 35 patients were enrolled, of whom 3 did not meet the required eligibility criteria and 2 were not evaluable. The 3 ineligible patients had preoperative CTC assessment performed based on staging as locally advanced EC and were then confirmed to have synchronous stage I endometrial and stage III or IV ovarian/ primary peritoneal cancers. Of the 2 patients that were not evaluable, 1 consented but did not have a further blood test for CTC collection, and the other had a sample collected, but the CellSearch system malfunctioned at the time of analysis.
CTC Enumeration
The CTC results for the remaining 30 patients included 3 with locally advanced disease and 27 with metastatic disease. Eighteen of the 30 patients (60%) were CTC positive (CTC+), all of whom had metastatic disease. Seven of these 18 patients (39%) were positive for 1 CTC per 7.5 ml blood, 4 (22%) had 2 CTCs, 1 had 3 CTCs (5.6%), 2 had 4 CTCs (11%) and 1 each (5.6%) had 7 CTCs, 8 CTCs, 22 CTCs and 172 CTCs per 7.5 ml blood.
Differences in the clinical course at the time of CTC collection for the CTC+ and CTC-negative (CTC-) patients are outlined in table 1 . At the time of first CTC collection, all CTC+ patients had either newly diagnosed stage IV or recurrent metastatic (RM) disease compared to the 75% (9 from 12) of CTC-patients who had stage IV or RM disease. Grade 3 disease and the presence of peritoneal and liver metastases were also more common in CTC+ patients.
For patients whose samples were collected after disease recurrence, average time to recurrence was shorter in CTC+ patients at 20.3 months (11 patients, range 9-38 months) compared to 30.8 months (6 patients, range 5-95 months) in CTC-patients. The hazard ratio for re- Survival status with stage IV disease based on f/u time from diagnosis of metastases 2 from 9 died at >12 months (mean 13 months) 5 alive at ≤12 months f/u 2 alive at >12 months f/u (mean 15 months f/u time)
6 from 18 died at ≤12 months 2 died at >12 months (mean 9 months for these 8 patients) 9 alive at ≤12 months f/u 1 alive at >12 months f/u (mean 8. More CTC-patients were alive at last follow-up compared to CTC+ patients. For patients who had died during follow-up, more CTC+ patients were deceased within 12 months after diagnosis with stage IV or RM disease compared to CTC-patients. The hazard ratio for survival was 3.3, favouring the CTC-patients [p > 0.05, 95% CI 0.7-16.2]. The small sample size and short follow-up time limit the statistical analysis of these data.
In terms of histopathologic parameters, there were more NEEC than EEC tumours [14/18 (78%) 
CTC Molecular Profiling
From the 18 patients who were CTC+, 10 patients had CTCs with stathmin expression. Eight of these patients had all CTCs stain positive with stathmin, while the remaining 2 patients had 2 from 4 cells stain positive for stathmin. This is detailed in table 2 . One patient was stathmin negative. Seven patients did not have stathmin assessed due to supply restrictions: 3 patients with CTC 1, 1 patient with CTC 3 and patients with CTC 7, 8 and 22. 
Correlation of EpCAM and Stathmin IHC with CTC Status
The TIS for EpCAM and stathmin IHC was evaluated for 21 cases for which the blocks were available. Of the 18 CTC+ patients, 12 were sampled before and during first-line chemotherapy for metastatic EC, and 1 patient had follow-up samples taken during clinical trial involvement (all marked with an asterisk in table 2 ). Of the other 5, 1 developed detectable CTCs during followup but did not have further treatment, and the other 4 patients were CTC+ at baseline but died without further follow-up.
For the 13 CTC+ patients during treatment, 8 patients demonstrated changes in their CTC counts over time that were concordant with their clinical and radiological progress. Five from the 8 patients had positive baseline CTC counts that decreased during first-line chemotherapy and correlated with a partial response on imaging. One of these patients then had a CTC rise on 3rd follow-up with disease progression and died. One patient was CTC+ at baseline with a further increase during chemotherapy and died. One patient was CTC-with stable disease during first-line chemotherapy but had increased CTCs after chemotherapy with disease progression and died. The clinical trial patient had disease progression before trial with a positive CTC value that became negative after 1 month on trial corresponding with a partial response on imaging. The other 5 from 13 CTC+ patients had changes in CTC counts that did not correlate with their clinical picture.
For the 12 patients who were CTC-at baseline and in follow-up, 7 had a clinical and/or radiological picture that correlated with the CTC result, 1 had a discordant picture and 4 had only a single CTC assessment, and evaluation of concordance was limited. This is also outlined in table 2 .
Discussion
Our study not only demonstrates the feasibility of CTC detection in EC on the CellSearch platform but importantly, of CTC MP with stathmin, which has potential utility across tumour types as a marker of PI3K pathway activity.
The PI3K/AKT/mammalian target of rapamycin (mTOR) pathway is one of the most studied pathways in EC with aberrations including oncogenic PIK3CA mutations and PTEN loss of function. However, reproducible, predictive and time-and cost-efficient markers of PI3K pathway activation remain elusive. The finding of stathmin overexpression in this study is a novel one and is the first report in EC CTCs and in CTCs in general. The next challenge in translating stathmin into a usable biomarker is to correlate CTC stathmin positivity with PI3K pathway activity to see whether CTC stathmin status could be used to predict response to agents targeting the PI3K/ Akt/mTOR pathway.
To this end, we assessed stathmin overexpression on FFPE tissue as this is a known prognostic marker in EC with evidence of predictive utility in response to taxanes. Our finding of stathmin overexpression on FFPE EC was 47%, consistent with the literature reports of overexpression in between 27 and 57% of primary tumours [21, 30] . Interestingly, CTC positivity was associated with higher stathmin IHC TIS, consistent with the prognostic association of stathmin overexpression and the worse clinical outcome of CTC+ patients here. Further work, however, is required to better define this relationship and may in fact be worthy of investigation across tumour types including breast and prostate cancer, where CTCs have already demonstrated prognostic utility and activity of the PI3K pathway is also well documented [31, 32] . CTC positivity in EC has also been demonstrated by Bogani et al. [33] using the Janssen CellSearch platform. They reported positive CTCs in 2 from 28 (7%) EC patients preoperatively, both having grade 3, stage IIIC, EEC. They also found an association with deep MMI and lymph node positivity. Of note, of the patients included in this study, 18 had stage I disease, 1 had stage II, 6 had stage III and 3 had stage IV disease. In contrast, we demonstrated CTC positivity in 60% of patients with stage IV or RM EC, both in EEC and NEEC. Patients with advanced EC were selected here, aiming to increase the detection of patients with CTC positivity that could then be followed longitudinally and have MP performed.
Furthermore, in a subset of patients receiving first-line chemotherapy for metastatic disease, we were able to demonstrate that longitudinal assessment of CTCs correlated with clinical outcome. Interestingly, there was a trend between CTC positivity and higher-stage, grade 3 disease, NEEC histology, shorter time to recurrence and reduced survival.
There were also patients, however, whose CTC followup did not correlate with their clinical course, and a number of factors in our study that did not correlate with CTC positivity, including MMI, lymphovascular space invasion and cervical invasion, all being traditional parameters currently used to guide primary treatment after surgery. This may reflect the limitations of these traditional pathologic factors in guiding primary treatment or limitations in CTC evaluation and our sample size.
This study demonstrates the presence of CTCs in EC using the EpCAM-based CellSearch platform as well as early clinical correlation patterns. Important to the utility of the CellSearch platform is the presence of EpCAM, and overexpression was reported in 86% of the archival FFPE tissue here, consistent with the published literature of moderate to intense EpCAM overexpression in 80-88% [10, 34] of EC specimens. However, it is known that down-regulation of EpCAM occurs when cancers and CTCs undergo epithelial-mesenchymal transition and develop a more invasive phenotype with metastatic potential. In a comparison of EpCAM expression on CTCs versus FFPE tissue and other benign disease, EpCAM expression was demonstrated to be 10-fold lower on CTCs compared to primary or metastatic tissue [35] . Despite such potential limitations, an EpCAM detection system may still be preferred in EC, particularly with its high rate of EpCAM overexpression, though other techniques now warrant investigation to determine the optimum method for this cancer type and whether a certain platform is better for enumeration or isolation for MP. This may include other EpCAM-based techniques such as the Gilupi nanodetector [36] or techniques based on physical properties such as the ISET (isolation by size of epithelial tumour cells) system [37, 38] , dielectrophoretic field flow fractionation methods [39, 40] , and Imagestream (Amnis) that combines flow cytometry and fluorescent microscopy in a single platform [41] . In terms of CTC MP, although the use of an antibody within the fourth channel on the CellSearch platform is the most time-efficient, it only allows analysis for a single antibody per blood sample, and each antibody must be appropriately validated for use on CTCs. Further techniques have been described to extract CTCs from the CellSearch magnetic cartridge and perform further MP [3, 5, 6] .
Although the small patient number here limits statistical power, correlation of CTC stathmin positivity with outcomes with both chemotherapy and PI3K pathwaytargeted agents in EC and other tumours is worthy of further exploration. The ability to detect stathmin on CTCs, the reproducibility of staining and evidence as a marker of PI3K activation [26] make stathmin an attractive choice of antibody.
Longitudinal tissue analysis of EpCAM and PI3K alterations and mapping CTC molecular analysis could provide strong evidence for using CTCs and their MP as a so-called 'liquid biopsy' to predict response to standard chemotherapy and molecularly targeted agents for each patient.
If validated in larger studies, longitudinal evaluation of CTCs, stathmin expression and correlation with treatment outcome may provide the first predictive biomarker for treatment response in EC and act as a surrogate marker for survival in those patients who are CTC+. CTCs and their stathmin expression along with further MP could be incorporated into clinical trials that assess PI3K pathway-targeting agents and other molecularly targeted agents with the potential of better streamlining clinical trial and drug development.
